SCHEDULE 13G/A: Avidity Partners Discloses 6.6% Stake in Immunic, Inc. Common Stock
Beneficial Ownership Disclosure
Avidity Partners Management LP and related entities, including Michael Gregory, have filed an amended Schedule 13G disclosing a beneficial ownership of 6.6% in Immunic, Inc.'s common stock as of March 31, 2025.
Summary
- Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, and Michael Gregory collectively reported beneficial ownership of 6,041,059 shares of Immunic, Inc. common stock.
- This aggregate ownership represents 6.6% of Immunic, Inc.'s outstanding common stock.
- Avidity Private Master Fund I LP, a related entity, separately reported beneficial ownership of 4,699,532 shares, representing 5.2% of the class.
- All reporting persons, including Michael Gregory, hold shared voting and shared dispositive power over their respective reported shares.
- The filing is an Amendment No. 3 to a Schedule 13G, indicating a change in previously reported beneficial ownership.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of Immunic, Inc., as certified by the reporting persons.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive investment stake by an institutional investor in a publicly traded company, common in the financial industry for transparency regarding large holdings.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement (beneficial ownership calculation date). |
| 05/15/2025 | Date of signing and filing of the Schedule 13G Amendment No. 3. |
Keywords
Beneficial Ownership, Schedule 13G, SEC Filing, IMMUNIC, INC., Avidity Partners Management LP, Common Stock, Institutional Ownership, Investment Disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.